Market Closed -
Japan Exchange
07:00:00 02/05/2024 BST
|
5-day change
|
1st Jan Change
|
136
JPY
|
0.00%
|
|
-4.23%
|
+1.49%
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
14,487
|
14,930
|
14,460
|
5,296
|
5,296
|
-
|
Enterprise Value (EV)
1 |
13,680
|
14,569
|
13,973
|
5,296
|
5,296
|
5,296
|
P/E ratio
|
-1.98
x
|
-14.5
x
|
-26.5
x
|
-4.98
x
|
194
x
|
7.73
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
13.5
x
|
15
x
|
9.22
x
|
1.89
x
|
1.96
x
|
1.54
x
|
EV / Revenue
|
13.5
x
|
15
x
|
9.22
x
|
1.89
x
|
1.96
x
|
1.54
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-10,925,318
x
|
-11,765,066
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
10.1
x
|
9.99
x
|
9.43
x
|
6.33
x
|
6.13
x
|
-
|
Nbr of stocks (in thousands)
|
27,647
|
29,623
|
31,435
|
38,940
|
38,940
|
-
|
Reference price
2 |
524.0
|
504.0
|
460.0
|
136.0
|
136.0
|
136.0
|
Announcement Date
|
25/05/20
|
13/05/21
|
12/05/22
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
1,077
|
996.5
|
1,569
|
2,808
|
2,696
|
3,439
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-1,161
|
-969.7
|
-919
|
-838
|
43
|
574
|
Operating Margin
|
-107.8%
|
-97.31%
|
-58.57%
|
-29.84%
|
1.59%
|
16.69%
|
Earnings before Tax (EBT)
|
-7,314
|
-999
|
-533
|
-
|
-
|
-
|
Net income
1 |
-7,316
|
-1,001
|
-535
|
-858
|
23
|
554
|
Net margin
|
-679.29%
|
-100.49%
|
-34.1%
|
-30.56%
|
0.85%
|
16.11%
|
EPS
2 |
-264.6
|
-34.79
|
-17.35
|
-27.30
|
0.7000
|
17.60
|
Free Cash Flow
|
-1,326
|
-1,269
|
-
|
-
|
-
|
-
|
FCF margin
|
-123.12%
|
-127.34%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/05/20
|
13/05/21
|
12/05/22
|
-
|
-
|
-
|
Fiscal Period: March |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
807
|
361
|
487
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-1,326
|
-1,269
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-512%
|
-64.7%
|
-35.4%
|
-77.6%
|
3.3%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-25.8%
|
-25.6%
|
-29.8%
|
1%
|
-
|
Assets
1 |
-
|
3,886
|
2,089
|
2,879
|
2,300
|
-
|
Book Value Per Share
2 |
51.70
|
50.40
|
48.80
|
21.50
|
22.20
|
-
|
Cash Flow per Share
|
-265.0
|
-34.80
|
-17.30
|
-
|
-
|
-
|
Capex
|
1.94
|
2
|
-
|
-
|
-
|
-
|
Capex / Sales
|
0.18%
|
0.2%
|
-
|
-
|
-
|
-
|
Announcement Date
|
25/05/20
|
13/05/21
|
12/05/22
|
-
|
-
|
-
|
Average target price
800
JPY Spread / Average Target +488.24% Consensus |
1st Jan change
|
Capi.
|
---|
| +1.49% | 33.6M | | -1.33% | 104B | | +4.97% | 97.47B | | +5.71% | 22.25B | | -13.49% | 21.68B | | -9.70% | 18.2B | | -39.98% | 17.02B | | -10.67% | 16.36B | | +8.76% | 14.39B | | +39.76% | 12.37B |
Bio Therapeutic Drugs
|